Document is current
Any future updates will be listed below
-
Authors
Dharan, Nila J. https://orcid.org/0000-0003-1175-5962
Radovich, Tomas
Che, Samuel
Petoumenos, Kathy
Juneja, Prabhjot
Law, Matthew
Huang, Robin
McManus, Hamish
Polizzotto, Mark N.
Guy, Rebecca
Cronin, Peter
Cooper, David A.
Gray, Richard T.
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme
Kirby Institute, University of New South Wales
- License Information
-
More Information
Article History
Received: 4 September 2018
Accepted: 14 December 2018
First Online: 3 January 2019
Ethics approval and consent to participate
: This project was approved by the Australian Government Department of Human Services External Review Evaluation Committee (MI6520). There were no permissions needed to obtain the data used in the study.
: Not applicable
: TR, SC, PS and PC are Prospection employees that were paid to undertake the analysis. KP received consultancy fees from ViiV Healthcare in 2017 and KPs organization has received unrestricted research funding from a pharmaceutical consortium that includes ViiV healthcare, Merck Sharpe and Dohme, and Janssen. MNP has received research funding and support from Celgene, ViiV healthcare, Janssen, and Gilead, and has served on speaker bureaus or advisory boards for Gilead, Amgen, and Celgene. ML has received unrestricted grants from Boehringer Ingelhiem, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag, ViiV HealthCare, and has received consultancy and presentation fees from Gilead Sciences, and DSMB sitting fees from Sirtex Pty Ltd. RTG has received research funding from The World Bank Group, UNAIDS, Australian Department of Health, NSW Department of Health, and Gilead. None of the other authors have anything to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
